Orforglipron lowered blood pressure across hypertension stages in ATTAIN trials
_Image credit: Pharmacy Times_
Post hoc analyses of the ATTAIN-1 and ATTAIN-2 trials, shown at the AHA meeting, found orforglipron (Foundayo) cut systolic blood pressure by 6.1 and 4.9 mm Hg over 72 weeks, against 0.8 and 1.5 mm Hg on placebo. Weight loss explained roughly 58% to 81% of the drop, suggesting part of the effect is independent of weight. Pharmacy Times notes this matters for patients already on blood pressure medicines, whose regimens may need review as weight comes down.
Source: Pharmacy Times (8 Nov 2026). Image: Pharmacy Times.